# Incyte account plan

> Incyte is a Wilmington, Delaware biopharma company in hematology, oncology and immunology: FY2025 total revenues $5,141.2 million, 2,844 employees.

## At a glance

Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware that discovers, develops and commercializes therapeutics in three areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its anchor product is JAKAFI (ruxolitinib), whose patents expire in 2028, alongside the OPZELURA cream, NIKTIMVO, MONJUVI/MINJUVI, ZYNYZ, ICLUSIG and PEMAZYRE, plus royalties from Novartis and Eli Lilly. FY2025 total revenues were $5,141.2 million (FY2024: $4,241.2 million) and net income $1,286.7 million. It had 2,844 employees at year-end 2025, 70% in the U.S. and Canada, with European headquarters in Morges, Switzerland. William (Bill) Meury has been President and CEO since June 2025.

## Business units

- **Hematology** (about 69% of 2025 total revenues): JAKAFI ($3,092.5 million in 2025) for myelofibrosis, polycythemia vera and GVHD, plus ICLUSIG, MONJUVI/MINJUVI and NIKTIMVO. Jakafi XR launched in the second quarter of 2026, and the mutCALR antibody INCA033989 and latarcibart (von Willebrand disease) are in Phase 3.
- **Oncology** (about 3% of 2025 total revenues): PEMAZYRE for FGFR2-fusion cholangiocarcinoma and ZYNYZ for Merkel cell and anal canal carcinoma; ZYNYZ reached $58.3 million in Q3 2026 (+157%). Pipeline includes the KRAS G12D inhibitor INCB161734 and the TGFβR2xPD-1 bispecific INCA33890, forming a GI oncology franchise.
- **Inflammation and Autoimmunity (IAI)** (about 13% of 2025 total revenues): OPZELURA (ruxolitinib) cream for atopic dermatitis and vitiligo, $678.5 million in 2025 and $254.9 million in Q3 2026 (+36%). Povorcitinib (oral JAK1) for hidradenitis suppurativa has a positive CHMP opinion, with U.S. approval expected in Q1 2027.
- **Royalties and partnered programs** (about 12% of 2025 total revenues): Royalties of $636.9 million in 2025 on JAKAVI and TABRECTA (Novartis) and OLUMIANT (Eli Lilly), plus milestone and contract revenues of $150.0 million.

## Strategic priorities

- **Offset JAKAFI exclusivity loss**: The company says it must develop new products to offset the loss of JAKAFI exclusivity in 2028; it aims to retain 10%-30% of the Jakafi business by 2029 through Jakafi XR.
- **Scale the core business beyond Jakafi**: Core business ex-Jakafi was $490 million in Q3 2026 (+30%); Meury sees it growing to $3 billion-$4 billion by 2030.
- **Late-stage pipeline execution**: Six assets in Phase 3, including povorcitinib, INCA033989 (mutCALR), the KRAS G12D inhibitor and latarcibart; Meury says the risk managed is increasingly execution of Phase III programs.
- **Expand Opzelura**: Deliberate 2026 investment in a bigger sales force, NP/PA promotion and formulary quality; the EU approved Opzelura for moderate AD in July 2026.
- **Business development**: Meury views BD as "a multiplier"; Vega Therapeutics was acquired in July 2026 for $1.25 billion.

## Latest results

Q3 2026 total revenue was $1.56 billion and total net sales $1.32 billion, each up 14% versus Q3 2025. Jakafi/Jakafi XR net sales were $827 million (+4%) with paid demand up 12%, Opzelura $255 million (+36%) and Hematology and Oncology $235 million (+38%). The quarter showed a GAAP net loss of $784.8 million because of a one-time $1.23 billion IPR&D expense for the Vega Therapeutics acquisition; nine-month GAAP net income was $104.1 million. Guidance for 2026 was raised to total net sales of $5,210-5,300 million, Opzelura $1,100-1,120 million and Hematology and Oncology $890-910 million, with Jakafi unchanged at $3,220-3,270 million. Cash and marketable securities were $3.9 billion at September 30, 2026.

## Investments and deals

- **Vega Therapeutics acquisition**: Acquired in July 2026 for $1.25 billion plus up to $750 million in sales milestones, adding latarcibart for von Willebrand disease (Phase 3 topline in early 2029).
- **Late-stage R&D**: R&D expenses were $2,050.2 million in 2025; GAAP R&D excluding the Vega charge rose 11% in Q3 2026 on late-stage development.
- **Partnerships and licensing**: Enable Injections enFuse on-body delivery license for INCA033989 (October 2025) and the Lilly baricitinib amendment with a $100.0 million upfront.
- **Novartis settlement**: In May 2025 Incyte paid $280.0 million for disputed royalties and the royalty rate on future U.S. JAKAFI sales was cut by 50%.

## Challenges and risks

- **JAKAFI dependence**: JAKAFI was $3,092.5 million of 2025 revenues and its patents expire in mid and late 2028.
- **Drug pricing pressure**: Medicare and Medicaid reforms, most favored nation proposals and PBM formulary control; an August 2026 CMS agreement aligned Medicaid Jakafi prices with other industrialized nations.
- **Pipeline attrition**: Meury said "attrition is a fact of life"; CDK2 enrollment in platinum-resistant ovarian cancer was discontinued and prurigo nodularis development for ruxolitinib cream was paused.
- **Supply concentration**: Manufacturing is largely outsourced, ruxolitinib raw materials come from Chinese suppliers, and ZYNYZ and NIKTIMVO each rely on one qualified API maker; a European supplier is being qualified.

## What leadership says

> "gives us the scale to navigate the 2029 transition and fund R&D" — Bill Meury, President and CEO, On the core business, Q3 2026 earnings call, October 29, 2026

> "we view BD as a multiplier, a way to extend and strengthen the core" — Bill Meury, President and CEO, Q4 2025 earnings call, February 10, 2026

> "We can't declare victory yet." — Bill Meury, President and CEO, On the Phase 3 pipeline, Q3 2026 earnings call, October 29, 2026

> "what we're solving for is the steepest possible growth curve post '29 and durable earnings and cash flow" — Bill Meury, President and CEO, Q4 2025 earnings call, February 10, 2026


## Where a supplier can help

- **Clinical trial execution**: Tied to the late-stage pipeline priority: CROs, site networks and trial technology that help enrol Phase 3 programs on time fit management's focus on execution.
- **Launch and commercial support**: Tied to the Opzelura expansion and upcoming povorcitinib and Monjuvi launches: field force tools, patient access services (benefit verification, prior authorisations) and promotion fit the launch plan.
- **Supply chain diversification**: Tied to the supply concentration challenge: additional qualified API and drug-product manufacturers would reduce single-source exposure.
- **Pricing and market access analytics**: Tied to the drug pricing challenge: gross-to-net, rebate and access analytics support management of Medicaid and Medicare rules.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm)

Annual report · 2026-02-10

- Incyte is a Wilmington, Delaware-based global biopharmaceutical company that discovers, develops and commercializes proprietary therapeutics in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI); it reports one operating segment.
- FY2025 total revenues were $5,141.2 million (FY2024: $4,241.2 million); total product revenues, net were $4,354.3 million, product royalty revenues $636.9 million and milestone and contract revenues $150.0 million.
- JAKAFI (ruxolitinib) remains the anchor at $3,092.5 million of net revenues in 2025; its composition-of-matter and salt patents expire in mid and late 2028, and the company says it must develop new products to offset the loss of JAKAFI exclusivity in 2028.
- Growth brands: OPZELURA cream $678.5 million (of which $130.0 million outside the U.S.), NIKTIMVO $151.6 million in its launch year, MINJUVI/MONJUVI $144.6 million, ICLUSIG $134.1 million, PEMAZYRE $86.7 million, ZYNYZ $66.3 million.
- Net income was $1,286.7 million (diluted EPS $6.41) versus $32.6 million in 2024, helped by a $242.2 million contract dispute settlement gain with Novartis, which also halved the royalty rate on future U.S. JAKAFI sales from January 1, 2025.
- R&D expenses were $2,050.2 million and SG&A $1,376.2 million; cash, cash equivalents and marketable securities reached $3,580.6 million at December 31, 2025, with no borrowings under a $500.0 million revolving credit facility.
- Late-stage pipeline: povorcitinib (HS, vitiligo, PN, asthma), INCA033989 (mutCALR antibody, Breakthrough Therapy designation in ET), INCB161734 (KRAS G12D) in PDAC, INCA33890 (TGFβR2xPD-1) in MSS colorectal cancer, INCB123667 (CDK2) in ovarian cancer, tafasitamab in first-line DLBCL, ruxolitinib XR.
- 2,844 employees at year-end 2025 (up approximately 9%): 70% in the U.S. and Canada, 27% in Europe, 3% in Asia; manufacturing is largely outsourced, with an own biologics plant in Yverdon, Switzerland.
- Key risks: dependence on JAKAFI, drug-pricing pressure (Medicare, Medicaid line-extension dispute on OPZELURA, most favored nation proposals), reliance on specialty pharmacies, wholesalers and single-source contract manufacturers (ruxolitinib raw materials come from Chinese suppliers).

### [Third Quarter 2026 Financial Results press release (8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000063/incy-q32026xexx991.htm)

Interim report · 2026-10-29

- Q3 2026 total revenue was $1.56 billion and total net sales $1.32 billion, each up 14% versus Q3 2025.
- Jakafi/Jakafi XR net sales were $827 million (+4%), with paid demand up 12%; Jakafi XR launched in the second quarter of 2026.
- Core business beyond Jakafi grew: Opzelura $255 million (+36%) and Hematology and Oncology $235 million (+38%), led by Niktimvo ($67.4 million), Zynyz ($58.3 million) and Monjuvi/Minjuvi ($54.6 million).
- GAAP net loss of $784.8 million (diluted EPS -$3.86) because of a one-time $1.23 billion IPR&D expense for the Vega Therapeutics acquisition (latarcibart for von Willebrand disease), bought for $1.25 billion plus up to $750 million in sales milestones.
- 2026 guidance raised: total net sales $5,210-5,300 million, Opzelura $1,100-1,120 million, Hematology and Oncology $890-910 million; Jakafi $3,220-3,270 million unchanged.
- August 2026 agreement with CMS: Medicaid gets Jakafi at prices aligned with other industrialized nations, and Incyte expects to be exempt from certain future CMS pricing mandates (GUARD and GLOBE).
- Pipeline: Phase 3 for INCA033989 in ET started mid-2026 and in MF by year-end; DAWN-303 (KRAS G12D, first-line PDAC) ongoing; NEXERA-303 (TGFβR2xPD-1, MSS CRC) ongoing; CDK2 refocused on first-line maintenance ovarian cancer.
- Regulatory: Opzelura approved in the EU for moderate AD (July); positive CHMP opinion for povorcitinib in HS; U.S. approvals of povorcitinib (HS) and Monjuvi in first-line DLBCL anticipated in Q1 2027.
- Cash, cash equivalents and marketable securities of $3.9 billion at September 30, 2026.

### [Incyte Q3 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/10/29/incyte-incy-q3-2026-earnings-call-transcript/)

Executive talk · Bill Meury, Chief Executive Officer · 2026-10-29

- CEO Bill Meury restated a two-part strategy: scale the core business beyond Jakafi and advance the late-stage pipeline; the core business "gives us the scale to navigate the 2029 transition and fund R&D".
- Q3 2026: total revenue $1.56 billion (+14%), Jakafi franchise $827 million (+4%, demand +12%), core business ex-Jakafi $490 million (+30%), Opzelura $255 million (+36%).
- Meury sees the core business ex-Jakafi growing to $3 billion-$4 billion by 2030, and aims to retain 10%-30% of the Jakafi business by 2029 through Jakafi XR (about $50 million of XR net sales targeted for 2026).
- Six assets in Phase 3; Meury ranks povorcitinib, the mutCALR antibody 989, the G12D inhibitor and latarcibart as higher probability, TGFβxPD-1 as higher biology risk and CDK2 as incremental.
- Opzelura: deliberate 2026 investment in a bigger sales force, NP/PA promotion and formulary quality; about 20,000 prescribers and "north of a quarter of a million" patients; price to be a "maintenance strategy" from 2027.
- R&D head Pablo Cagnoni: building a GI oncology franchise around 734 (KRAS G12D) and 890 (TGFβR2xPD-1); next-gen CALR antibody to the clinic in early 2027 with pivotal trials targeted in 2028.
- Povorcitinib HS label: two scenarios (pre- and post-biologic, or post-biologic only), both "workable"; U.S. approval expected Q1 2027.
- 2026 total net sales guidance raised to $5.210 billion-$5.300 billion; operating expenses expected toward the middle of the range.

### [Incyte Q4 2025 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/02/10/incyte-incy-q4-2025-earnings-call-transcript/)

Executive talk · William Meury, Chief Executive Officer · 2026-02-10

- CEO Bill Meury (call of February 10, 2026): FY2025 revenue $5.14 billion (+21%), net sales $4.35 billion (+20%), "exceeding both expectations and our guidance"; Q4 revenue $1.51 billion (+28%).
- Jakafi 2025 sales $3.093 billion (+11%); 2026 guidance $3.22-3.27 billion; PV penetration of "only 30%" versus 60-70% in frontline MF; Jakafi XR conversion target 10-30%.
- Core business ex-Jakafi expected to grow over 30% in 2026, with the potential of a 15-20% five-year CAGR to $3-4 billion by 2030, "as large as Jakafi is today".
- 2026 guidance at the time: revenue $4.77-4.94 billion (+10-13%), Opzelura $750-790 million, Hematology/Oncology $800-880 million; GAAP R&D plus SG&A $3.495-3.675 billion, R&D up roughly 10%, G&A down 10%.
- Opzelura 2025 net sales $678 million (+33%); international vitiligo sales doubled to $130 million; Meury sees roughly $300 million of incremental international revenue over five years from moderate AD.
- Pipeline: 14 pivotal trials across seven assets by end-2026, seven data readouts, four potential launches in late 2026/early 2027; 80% of R&D spend goes to seven programs.
- Povorcitinib in HS: Meury targets the roughly 75% of patients not on an advanced systemic (antibiotics and steroids only).
- BD is "a multiplier"; G12D and TGFβxPD-1 address "the largest wide-open white spaces in cancer".

## Questions about Incyte

### What does Incyte do?

Incyte discovers, develops and sells medicines in hematology, oncology and inflammation and autoimmunity, including JAKAFI and the OPZELURA cream, and earns royalties on drugs licensed to Novartis and Eli Lilly.

### What is Incyte's revenue?

FY2025 total revenues were $5,141.2 million; 2026 total net sales guidance is $5,210-5,300 million.

### How many employees does Incyte have?

2,844 at December 31, 2025, up from 2,617 a year earlier.

### Who leads Incyte?

William (Bill) Meury has been President and CEO since June 2025; Pablo Cagnoni is President and Head of R&D.

### What is Incyte's strategy?

Scale the core business beyond Jakafi to $3 billion-$4 billion by 2030 and advance its late-stage pipeline to offset the 2028 loss of JAKAFI exclusivity.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
